加载中
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
前收盘价
US$6.07
−US$0.02 · -0.33%
盘前
US$6.04
−US$0.03 · -0.49%
10月8日 4:29 ET
盘中时间采用ET。市场数据可能有所延迟。
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
日内区间
当前US$6.07
52周区间
当前US$6.07
盘中时间采用ET。市场数据可能有所延迟。
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
日内区间
当前US$6.07
52周区间
当前US$6.07
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | — | — | — | 57.42万 USD | 29.42万 USD |
| 毛利 | — | — | — | 57.42万 USD | 29.42万 USD |
| 研究与开发 | 191.2万 USD | 221.2万 USD | 252万 USD | 274.5万 USD | 234.1万 USD |
| 销售、一般及管理费用 | 729.36万 USD | 934.14万 USD | 1263.66万 USD | 1247.29万 USD | 1071.51万 USD |
| 营业费用 | 729.36万 USD | 934.14万 USD | 1263.66万 USD | 1247.29万 USD | 1071.51万 USD |
| 利息收入 | 15.65万 USD | 29.81万 USD | 42.84万 USD | 1.1万 USD | — |
| 利息支出 | 1.44万 USD | 1.01万 USD | — | — | — |
| 折旧和摊销 | 32.37万 USD | 33.96万 USD | 35.91万 USD | 24.09万 USD | 12.37万 USD |
| 营业利润 | −729.36万 USD | −934.14万 USD | −1263.66万 USD | −1189.86万 USD | −1042.09万 USD |
| 净利润 | −715.15万 USD | −1338.81万 USD | −1220.82万 USD | −1202.98万 USD | −1041.61万 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
